Vestal Point Capital, LP Arcellx, Inc. Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,387,720 shares of ACLX stock, worth $162 Million. This represents 11.19% of its overall portfolio holdings.
Number of Shares
2,387,720
Previous 475,000
402.68%
Holding current value
$162 Million
Previous $36.4 Billion
329.99%
% of portfolio
11.19%
Previous 2.16%
Shares
5 transactions
Others Institutions Holding ACLX
# of Institutions
213Shares Held
48.7MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$305 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$271 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$255 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$239 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$206 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.98B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...